Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment?
Riccardo NevolaAntonio RussoSamuel ScuottoSimona ImbrianiConcetta ApreaMarianna AbitabileDomenico BecciaChiara BrinCaterina CarusoneFrancesca CinoneGiovanna CiriglianoSara ColantuoniDomenico CozzolinoGiovanna CuomoMicol Del CoreKlodian GjeloshiAldo MarroneGiulia MedicamentoLuciana Agnese MeoFrancesco NappoAndrea PadulaPia Clara PafundiRoberta RanieriCarmen RicozziLuca RinaldiCiro Pasquale RomanoRachele RuoccoCarolina RuosiAnnabella SalvatiFerdinando Carlo SassoAusilia SellittoPino SommeseAngela VillaniNicola CoppolaLuigi Elio AdinolfiPublished in: Respiratory research (2022)
Starting CPAP/NIV in patients with SARS-CoV-2-related ARDS in moderate stage (100 > P/F ≤ 200) is associated to a reduction of both in-hospital mortality and hospitalization length compared to the severe stage (P/F ≤ 100). Starting CPAP/NIV with a P/F > 150 does not appear to be of clinical utility.